Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07771725

Impact of Sweeteners on the Addictive Threshold of Nicotine

To determine if sucralose, an artificial sweetener, modulates nicotine threshold doses for discrimination, subjective-rewarding effects, and reinforcement in smokers with varying levels of dependence.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

21 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

VA Hospital

West Haven, Connecticut, 06516, United States

About this study

Participants will complete an Adaptation Session followed by four Test Days. The Adaptation Session will familiarize participants with all study procedures. On each Test Day, a specific intravenous nicotine dose (0.05 or 0.1 mg/pulse) is paired with either a sucralose or control flavor administered by an electronic cigarette. The experimental procedure begins with a sampling phase comparing the assigned nicotine dose against saline, each paired with the assigned flavor, followed by four trials to assess the participant's ability to discriminate between the two conditions. Subsequently, participants complete four Choice trials, where they will choose between receiving the assigned nicotine dose and saline. Reinforcement will be measured by the percentage of nicotine choices, while discrimination will be measured by the percentage of correctly identified infusions. Subjective rewarding effects will be assessed using the "Pleasurable Effects" composite score of the Drug Effects Questionnaire (DEQ).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Smoking at least for one year and more frequently than once a week, smoking status confirmed with a semi-quantitative urine nicotine test. Smokers will be stratified by level of dependence, assessed with the FTND 29 low or no dependence ≤3 and moderate or high dependence ≥ 4.
  • In good health as verified by medical history, screening examination, and screening laboratory tests.
  • For women, report using acceptable birth control methods.

Exclusion criteria

  • History of major medical or psychiatric disorders that the physician investigator deems as contraindicated for the participant to be in the study;
  • regular current use of certain psychotropic medications (such as mood stabilizers, antipsychotics, or anxiolytics being prescribed to treat bipolar disorder, psychosis or anxiety spectrum disorders, respectively);
  • current untreated alcohol or substance use disorder for any other recreational or prescription drugs other than nicotine;
  • for women, pregnant as determined by pregnancy screening, or breastfeeding; and 5) seeking (or undergoing) treatment for tobacco dependence or smoking.

Treatment and study plan

Nicotine 0.05 mg/pulse and 0.1 mg/pulse

Drug

Nicotine will be used and compared to saline given by IV push by study physician

Saline Placebo (0.5mL injection)

Drug

Saline will be used compared to the low dose of Nicotine given by IV push by study physician

Sucralose

Dietary Supplement

sweet flavor (sucralose) compared to unsweetened flavor

Sugar syrup (Placebo)

Dietary Supplement

Unsweetened flavor compared to the sweetened flavor sucralose.

Primary outcomes

  1. Drug Discrimination Scale (DDS) score.

    Time frame: OnTest Days 1, 2, 3 and 4

    This scale asks the participants to select if they received Drug A or B and how confident they are in their selection on a scale of 0 to 10. Higher scores indicate more confidence.

  2. Drug Effects Questionnaire (DEQ) pleasurable effects score

    Time frame: OnTest Days 1, 2, 3 and 4

    The DEQ pleasurable effects consists of 11 questions with total score range from 0-100. Higher scores indicate more positive effects.

Secondary outcomes

  1. Minnesota Nicotine Withdrawal Scale score

    Time frame: OnTest Days 1, 2, 3 and 4

    This 8-item scale will be used to assess DSM-IV symptoms of nicotine withdrawal. Total score range 0-32. Higher scores indicate more severe withdrawal symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Mehmet Sofuoglu, M.D., Ph.D.

CONTACT

[email protected]

203-932-5711

Stacy A Minnix, B.S.

CONTACT

203--932-5711

Sponsors and collaborators

Lead sponsor

Yale University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Aug 18, 2026
Registry last updated
Aug 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.